Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Inclusion Criteria:

• Subjects with acute ischemic stroke, aging ≥ 19

• Confirmed to have acute anterior circulation cerebral artery occlusion in intracranialinternal carotid artery (IICA) or middle cerebral artery (MCA) M1 segment by CT or MRangiography.

• National Institutes of Health Stroke Scale(NIHSS) is 6~30 before endovascularrecanalization therapy (ERT)

• Subject who is reperfused with 2b or 3 stages of thrombolysis in cerebral infarction (TICI) (However, if angiography is conducted for thrombectomy after IV tPA treatmentand the effect of tPA results in TICI 2b-3 reperfusion, the subject can participate)

• Subject who can administer IP within 6.5 hrs of symptom development

• Subject who can administer IP within 30 min of vascular reperfusion

• Subject who can evaluate MRI within 90 min of vascular reperfusion

Exclusion Criteria:

• Subject who is contraindicated for endovascular recanalization

• Subject who has hypersensitivity to contrast agent or component of investigationalproduct

• Prohibited or unable to perform MRI test

• Medical history that is related to bleeding

• History of hemorrhagic stroke within 6 months of study participation

• Subjects with chronic liver disorder

• Kidney disorder (Serum creatinine > 3 mg/dL)

• Life expectancy is less than 3 months due to concomitant disease other than stroke

• Pregnant or lactating women

• Those who have taken tirofiban (anticoagulant agent) during endovascularrecanalization therapy

• Those who have taken other investigational drugs and/or medical instruments 12 weeksprior to screening

• Subject is unable to be followed up

• Subject is deemed unable to participate the study in the opinion of the investigator.